Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations
- PMID: 27386054
- PMCID: PMC4916257
- DOI: 10.3402/jmahp.v4.30725
Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations
Abstract
Background: There is controversy as to whether use of statistical clustering methods to identify common disease patterns in schizophrenia identifies patterns generalizable across countries.
Objective: The goal of this study was to compare disease states identified in a published study (Mohr/Lenert, 2004) considering US patients to disease states in a European cohort (EuroSC) considering English, French, and German patients.
Methods: Using methods paralleling those in Mohr/Lenert, we conducted a principal component analysis (PCA) on Positive and Negative Syndrome Scale items in the EuroSC data set (n=1,208), followed by k-means cluster analyses and a search for an optimal k. The optimal model structure was compared to Mohr/Lenert by assigning discrete severity levels to each cluster in each factor based on the cluster center. A harmonized model was created and patients were assigned to health states using both approaches; agreement rates in state assignment were then calculated.
Results: Five factors accounting for 56% of total variance were obtained from PCA. These factors corresponded to positive symptoms (Factor 1), negative symptoms (Factor 2), cognitive impairment (Factor 3), hostility/aggression (Factor 4), and mood disorder (Factor 5) (as in Mohr/Lenert). The optimal number of cluster states was six. The kappa statistic (95% confidence interval) for agreement in state assignment was 0.686 (0.670-0.703).
Conclusion: The patterns of schizophrenia effects identified using clustering in two different data sets were reasonably similar. Results suggest the Mohr/Lenert health state model is potentially generalizable to other populations.
Keywords: Europe; USA; disease states; outcome assessment; schizophrenia; validation.
Figures
Similar articles
-
Healthcare resource use in schizophrenia, EuroSC findings.J Mark Access Health Policy. 2017 Sep 5;5(1):1372027. doi: 10.1080/20016689.2017.1372027. eCollection 2017. J Mark Access Health Policy. 2017. PMID: 29081923 Free PMC article.
-
The heterogeneity of schizophrenia in disease states.Schizophr Res. 2004 Nov 1;71(1):83-95. doi: 10.1016/j.schres.2003.11.008. Schizophr Res. 2004. PMID: 15374576 Clinical Trial.
-
An excitement subscale of the Positive and Negative Syndrome Scale.Schizophr Res. 2004 Jun 1;68(2-3):331-7. doi: 10.1016/S0920-9964(03)00087-2. Schizophr Res. 2004. PMID: 15099614
-
[Caregiver burden in relatives of persons with schizophrenia: an overview of measure instruments].Encephale. 2003 Mar-Apr;29(2):137-47. Encephale. 2003. PMID: 14567165 Review. French.
-
The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.CNS Drugs. 2016 Jul;30(7):603-28. doi: 10.1007/s40263-016-0349-0. CNS Drugs. 2016. PMID: 27290715 Review.
Cited by
-
The multidimensional construct of resilience across the psychosis spectrum: Evidence of alterations in people with early and prolonged psychosis.Psychiatr Rehabil J. 2020 Sep;43(3):225-233. doi: 10.1037/prj0000393. Epub 2019 Nov 21. Psychiatr Rehabil J. 2020. PMID: 31750682 Free PMC article.
-
COSMIN systematic review and meta-analysis of the measurement properties of the Positive and Negative Syndrome Scale (PANSS).EClinicalMedicine. 2025 Apr 11;82:103155. doi: 10.1016/j.eclinm.2025.103155. eCollection 2025 Apr. EClinicalMedicine. 2025. PMID: 40255437 Free PMC article.
-
COSMIN review of the PANSS Marder factor solution and other factor models in people with schizophrenia.Schizophrenia (Heidelb). 2025 Mar 31;11(1):51. doi: 10.1038/s41537-025-00600-6. Schizophrenia (Heidelb). 2025. PMID: 40164635 Free PMC article.
-
Healthcare resource use in schizophrenia, EuroSC findings.J Mark Access Health Policy. 2017 Sep 5;5(1):1372027. doi: 10.1080/20016689.2017.1372027. eCollection 2017. J Mark Access Health Policy. 2017. PMID: 29081923 Free PMC article.
References
-
- Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, ‘just the facts’ 4. Clinical features and conceptualization. Schizophr Res. 2009;110(1–3):1–23. - PubMed
-
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76. - PubMed
-
- Overall JE, Gorham DR. Brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.
LinkOut - more resources
Full Text Sources
Other Literature Sources